Safety and efficacy of blinatumomab in the treatment of refractory systemic sclerosis: a case seriesMarc Scherlinger, Emmanuel Chatelus, Roberto D’Alessandro et al.|Annals of the Rheumatic Diseases|2026Cited by 5
POS1121 THE USE OF THE CD3/CD19 T CELL ENGAGER BLINATUMOMAB IN SEVERE SYSTEMIC SCLEROSIS: A CASE SERIESM. Scherlinger, J. Sibilia, Yannick Dieudonné et al.|Annals of the Rheumatic Diseases|2025Cited by 3